Neurological dysfunction in AIDS occurs in the absence
Introduction
Patients with AIDS dementia complex (ADC) manifest profound dysfunction of the central nervous system (CNS) that is often associated with productive human immunodeficiency virus type 1 (HIV-1) replication in macrophages and microglia (Koenig et al., 1986; Wiley et al., 1986; Gabudza et al., 1987; Pumarola-Sune et al., 1987; Achim et al., 1991) . Virus has been detected only rarely in the neurons of such patients (Wiley et al., 1986; Pumarola-Sune et al., 1987; Kato et al., 1987; Kure et al., 1990) and, although highly restricted infection of neurons cannot be excluded, this suggests that neuro-logical dysfunction may result via indirect pathways by which infected microglia interact with and alter normal functions of target neurons.
Potential trans-cellular mechanisms and mediators involved in neurological dysfunction in AIDS have been the subject of extensive investigation, and include viral and cellular products that may be released by productively infected cells within the CNS. Neuronal cell death is induced by the HIV-1 trans-activator protein Tat (Sabatier et al., 1991) , the envelope glycoprotein gpl20 (Lipton, 1991) , products of infected macrophages (Pulliam et al., 1991; Giulian et al., 1990) , arachidonic acid metabolites released in macrophage/astrocyte cocultures (Genis et al., 1992) and by direct contact with infected monocytic cells (Tardieu et al., 1992) . Alternatively, neurological dysfunction may result from disturbances in function independent of cell killing. Such a possibility is consistent with observations in vivo, in which dysfunction is frequently out of proportion to pathological lesions (Navia et al., 1986; Spencer & Price, 1992) . Either viral proteins or cellular factors produced by infected cells locally might be involved in induction of sub-lethal toxic effects in neurons (Merrill et al., 1989 (Merrill et al., , 1992 Molina et al., 1990; Pulliam et al., 1991) . Recently we demonstrated that exogenous recombinant Tat protein can induce morphological changes in neurons and astrocytes in developing rodent brain cell cultures without causing cell death, and that this function maps to its RGD (Arg-Gly-Asp) sequence , which is distinct from the trans-activation domain(s) (Green & Lowenstein, 1990) .
Tat up-regulates proviral gene expression and is essential for virus replication. In addition, several studies have demonstrated that Tat can alter cellular gene expression in a variety of non-neuronal cell types. It upregulates expression of extracellular matrix proteins in glial cells , tumour growth factor-ill (TGF-Ill) in lymphocytic cells, glial cells, and marrow macrophages (Cupp et al., 1993; Zauli et al., 1992) , interleukin-4 receptors in B lymphoblastoid cells (Purl & Aggarwal, 1992) , and tumour necrosis factor-il in T lymphocytic and B lymphoblastoid cells Sastry et al., 1990) . Tat has also been shown to down-regulate HLA class I promoter activity in HeLa cells (Howcroft et al., 1993) . Ensoli et al. (1990 Ensoli et al. ( , 1992 demonstrated that productively infected cells may release soluble Tat into the extracellular media, and that such extracellular Tat may be taken up by certain uninfected cells in a biologically active form capable of transactivation of the H1V-1 long terminal region (LTR) Frankel & Pabo, 1988; Mann & Frankel, 1991) . Transcellular trans-activation of the HIV-1 LTR through contact with Tat-expressing cells has also been demonstrated (Helland et al., 1991; Marcuzzi et al., 1992a, b) .
To explore the hypothesis that Tat may also modulate neuronal cell function through its trans-activational capacity, we examined the ability of both exogenous and endogenously produced protein to trans-activate Tatresponsive promoter constructs in human neuronal cells. We constructed human neuroblastoma (SK-N-MC) cell lines constitutively expressing Tat derived from two different virus strains, and examined its effect on LTRdriven gene expression as well as viral antigen production. In addition, we tested the ability of neuronal cells to take up exogenous Tat protein in a biologically active form. We found that both endogenously expressed and exogenous Tat can trans-activate the HIV-1 LTR in SK-N-MC neuronal cells, and are non-toxic to these cells at levels capable of trans-activation. Furthermore, after transfection with several proviral clones, Tat-expressing cells showed significantly greater HIV-1 p24 antigen production than control cells not expressing Tat. These observations support the hypothesis that neurons may be an additional cellular target in vivo for sub-lethal transcellular or intracellular modulation by Tat.
Methods
Plasmids. The CAT reporter construct pHIVCAT-SVNEO contains the chloramphenicol acetyl transferase (CAT) gene driven by the HIV-1 (strain IIIB) LTR, and a neomycin resistance gene (NEO) driven by the simian virus 40 (SV40) early promoter (gift of K. Valerie, SmithKline Beecham Pharmaceuticals). pSV~.neo contains the neomycin gene driven by the SV40 early promoter (Bacheler et al., 1989) . pSV2CAT contains CAT coupled to the SV40 early promoter (Gorman et al., 1982) . Tat expression plasmids all utilize the SV40 early promoter linked to the tat gene containing either both tat exons or only the first exon as follows: pSV2tat (strain IIIB, both exons, 86 amino acids; Bacheler et al., 1989) , pSV2tat72 (strain IIIB, first exon, 72 amino acids; Bacheler et al., 1989) , pTAT-1 (strain SF2, both exons, 106 amino acids; Peterlin et al., 1986) .
Cell lines. The SK-N-MC cell line is a peripheral neuroblastoma derivative that is CD4 and expresses the neuronal features of neurofilament proteins and neurotransmitter enzymes (Beidler et al., 1973 (Beidler et al., , 1978 . It was maintained in RPMI 1640 (Gibco), with 10% heatinactivated fetal bovine serum (Hyclone Laboratories), penicillin (100 U/ml), and streptomycin (100 U/ml). To derive stably transfected SK-N-MC ceil lines, approximately 5 x 10 ~ cells were co-transfected with pSV2neo (1 lag) and Tat plasmid (10 to 20 lag) using 10 gg/ml of Lipofectin reagent (Gibco BRL). After overnight incubation and 48 h of recovery they were placed under selection (G418,400 lag/ml) for 1 to 2 months. Tat-expressing lines were named for the plasmids contained therein: SK-N-MC/NEO contains pSV2neo alone, and SK-N-MC/NEO/TAT, SK-N-MC/NEO/TAT72 and SK-N-MC/NEO/ TAT-1 contain pSV2neo with pSV2tat, pSV2tat72 and pTAT-1, respectively. The SK-N-MC/CAT line contains pHIVCAT-SVNEO alone.
Tat protein and peptides. Recombinant Tat protein (rTat) is based upon the sequence of HIV-1 strain IIIB (86 amino acids) and was prepared in an Escherichia colt expression system as described (Aldovini et al., 1986) . Aliquots of purified protein were stored at -80 °C in Tat buffer (50 mM-Tris-HCl pH 8"0, 1 M-NaC1, adjusted to 20 % glycerol). Tat peptides are designated by the region they span: Tat 46-50, Tat 56-70 and Tat 73-86. Tat 46-60 and Tat 56-70 were purchased lyophilized (ABT and Repligen) and Tat 73-86 was synthesized at the University of Pennsylvania Protein Chemistry Laboratory. Peptides were reconstituted in Tat buffer.
Trans-acti~ation experiments.
For exogenous trans-activation, SK-N-MC/CAT cells, which contain the CAT gene under the control of the HIV-1 LTR, were cultured in six-well plates (approx. 5 x 105 cells/well, 50 to 75% confluence) in medium containing 100laM-chloroquine diphosphate (Frankel & Pabo, 1988 ) and exposed to rTat or synthetic peptide. Endogenous trans-activation was tested by transient transfection of approximately 5 x 105 Tat-expressing SK-N-MC cells with 1 to 12 lag of pHIVCAT-SVNEO using Lipofectin as described above. CAT activity was determined 24 h after transfection or treatment with exogenous protein or peptide. Cultures were then washed, scraped into assay buffer, subjected to freezing and thawing three times, and CAT activity was determined on cell lysates using a radioisotopic biphasic liquid extraction assay as previously described (Neumann et al., 1987; Kolson et al., 1994) . CAT activity was calculated as total c.p.m, above blank per unit protein in sample. Relative activity was expressed as a ratio of CAT activity in Tat-treated or transfected cells to activity in untreated control cells. For determination of transfection efficiency, SK-N-MC cell lines were similarly transfected with pSV~CAT (2 lag) and assayed 72 h later for CAT activity.
Virus expression. For proviral expression, approximately 0.1 to 2 lag of infectious cloned proviral HIV-1 DNA was transfected into SK-N-MC lines (approx. 105 cells in 24-well plates) using Lipofectin (8 ~g/ml) and a 14 h incubation. At intervals thereafter, cell-free supernatants were assayed for viral p24 Gag antigen content by antigen capture ELISA (Coulter). Proviruses used were pHXB2D, derived from the lymphocyte-tropic isolate IIIB (Shaw et al., 1984) , and p89.6 derived from the macrophage-tropic isolate 89.6 (Collman et al., 1992) . Transfection efficiency was determined by transfection in parallel with pSV2CAT as above. To test for infectious virus production, transfected cells were co-cultivated with CEMX174 cells, which are permissive for strains IIIB and 89.6 (Stefano et al., 1993) , and syncytium formation was scored visually. For HIV-1 infection, SK-N-MC cell lines were exposed for 4 h at 37 °C to cell-free viral stock at an m.o.i, of 0.5 TCIDs0/cell (as determined by endpoint dilution in CEMXI74 cells). Cells were then washed and fresh medium was added. Cells were split weekly and supernatants harvested for the p24 antigen measurement by ELISA.
Results

Exogenous Tat trans-activates LTR-driven gene expression in neuronal cells
To determine the ability of human neuronal cells to take up extracellular biologically active Tat, we tested whether exogenously applied rTat could trans-activate the LTR in SK-N-MC cells. SK-N-MC/CAT cells were exposed to rTat for various intervals, and CAT activity in cell lysates was assayed. Exposure to Tat at concentrations as low as 1 nM (0"01 gg/ml) produced efficient transactivation (Fig. 1 a) . Increasing levels of CAT activity were seen up to the maximum concentration tested, 200 nM (2 gg/ml). At this concentration, peak levels of CAT activity ranged from 80 to 1700-fold above basal levels in multiple experiments (see also Table 1 ). Increased CAT activity occurred within hours of exposure and was maximal at approximately 24 h (Fig. 1 b) . As expected, Tat peptides known to be incapable of trans-activation in other cell types (Frankel et al., 1989) were also inactive in SK-N-MC/CAT cells (Fig. 1 a) . A mutant full-length control Tat protein (86 amino acids) containing mutations only in the second exon, which is not important for trans-activation, was active (data not shown). Thus, human neuronal cells are capable of uptake and nuclear transport of biologically active exogenous Tat protein. As has been shown for nonneuronal cell types (Frankel & Pabo, 1988; Mann & Frankel, 1991) , maximum trans-activation by exogenous Tat in SK-N-MC/CAT cells required the presence of the lysosomotropic agent chloroquine diphosphate, with maximum trans-activation at a chloroquine concentration of 100 gM (Fig. 1 c) . Chloroquine is thought to inhibit proteolysis of internalized Tat, although the precise mechanism of its action is unknown (Frankel & Pabo, 1988) .
Binding of exogenous Tat occurs rapidly in SK-N-MC cells"
Since CAT expression increased over time and peaked 24 h after exposure, we wanted to determine whether this indicated inefficient uptake requiring prolonged exposure, or was related to the kinetics of later steps, such Cells were exposed to rTat (1 lag/ml) in the presence of chloroquine diphosphate (100 gM), and CAT activity was determined at various intervals thereafter. (c) Cells were exposed to rTat (1 gg/ml) with various concentrations of chloroquine diphosphate, and CAT activity was determined 24 h later. ~r CAT activity in cell lysates 25 h after initial Tat exposure, normalized for protein content.
:~ CAT activity in Tat-exposed cells normalized to control unexposed cells. as intracellular transport, trans-activation, or CAT expression. Parallel cultures of SK-N-MC/CAT cells were incubated with rTat for increasing time intervals followed immediately by extensive washing. CAT activity was assayed 25 h after initiation of exposure. As shown in Table 1 , 1 rain of exposure to Tat was sufficient for two-thirds of the maximum response and trans-activation was maximal after 15 min of exposure. Furthermore, addition of chloroquine up to 4 h after initial exposure to Tat resulted in similar levels of transactivation (data not shown). This suggests that the initial binding and/or internalization of Tat is efficient, and is not dependent upon chloroquine, which probably acts at later steps.
Endogenous Tat trans-activates LTR-driven gene expression in neuronal cells
To assess the ability of Tat produced endogenously within neuronal cells to trans-activate LTR-driven gene expression, we established neuroblastoma cell lines constitutively expressing Tat derived from two HIV-1 strains, IIIB and SF2. These stably transfected cells were then transiently transfected with pHIVCAT-SVNEO (Fig. 2) . SK-N-MC/NEO cells produced no CAT activity above background, whereas cells expressing Tat produced marked CAT activity (Fig. 2) , thus indicating endogenously expressed Tat-mediated trans-activation of the LTR. Transfection efficiency did not differ significantly among the cell lines: transfection of pSV2CAT resulted in levels of CAT activity that differed by less than threefold among the lines (Table 2) . Cell lines expressing Tat from strain SF2 (pTAT-1), or single exon or double exon Tat from IIIB (pSV2tat72 and pSV2tat ) all supported LTR-driven gene expression, but quantitative comparison of activity between the different plasmids tested was not possible, since levels of Tat produced within these cells under these conditions are not known. To ensure that endogenous Tat at levels sufficient for trans-activation did not have either toxic or growth-enhancing effects in neuronal cells, we compared growth rates of the cell lines. Both SK-N-MC/NEO and SK-N-MC/NEO/TAT grew at a rate identical to the parental SK-N-MC line (data not shown), indicating no gross toxic effects of endogenously produced Tat.
Tat enhances viral antigen release after provirus transfection in neuronal cells
Since both exogenous and endogenous Tat briskly stimulated LTR-driven gene expression in SK-N-MC cells, we determined whether constitutive expression of Tat would also up-regulate proviral gene expression. We introduced molecular clones of a lymphocyte-tropic (HXB2D) and a macrophage-tropic (89.6) virus into the cells by transfection and analysed the release of viral p24 antigen ( Fig. 3 and Table 2 ). Non-Tat-expressing SK-N- MC cells produced low antigen levels after transfection and, consistent with the LTR-CAT experiments, significantly higher levels of antigen were produced by Tatexpressing cells, suggesting up-regulation of viral transcription by Tat. We verified that infectious virus as well as p24 antigen was produced with each transfected provirus by demonstrating syncytium formation in CEMX174 cells co-cultured with the transfected SK-N-MC lines (data not shown).
To ensure that the higher levels of p24 antigen production in the Tat-expressing lines did not merely reflect a greater efficiency of transfection, each line was also transfected with the pSV2CAT plasmid and CATspecific activity in cell lysates was assayed (Table 2) . Up to 2.5-fold variation was seen in CAT activity within individual experiments, whereas consistently higher levels of p24 antigen were detected relative to CAT activity for all three Tat-expressing SK-N-MC lines, confirming that constitutive expression of Tat in these cells stimulated proviral LTR-driven gene expression.
Interestingly, exposure of SK-N-MC/NEO/TAT, SK-N-MC/NEO/TAT72 and SK-N-MC/NEO/TAT-1 cell lines to infectious virions (strain IIIB) did not increase the level of virus produced (data not shown), which is typically less than 200 pg/ml of p24 antigen in the parental SK-N-MC cells (Li et al., 1990; Harouse et al., 1991) . This suggests that although endogenous Tat expression enhances virus expression after transfection into SK-N-MC cells, it is unable to overcome the restriction to infection in these cells, which occurs at least in part at the level of entry (Li et al., 1990; Harouse et al., 1991) .
Discussion
We have shown that HIV-1 Tat markedly up-regulates LTR-driven gene expression in human neuronal cells, and that these cells are capable of efficient uptake of exogenous Tat protein in biologically active form. Both exogenous protein and endogenous Tat expression stimulated the LTR several hundred-fold at levels that were non-toxic to the cells, and as little as 1 min of exposure to rTat was sufficient for near-maximal transactivation. In addition, HIV-1 expression was augmented in neuronal cells that constitutively expressed Tat.
Because ADC is associated with productive virus replication in microglia and brain macrophages but not neurons or glia, soluble products of infected cells or viral proteins released by infected cells are believed to be responsible, at least in part, for neuronal dysfunction. Tat has been implicated as such a potential mediator. t Viral p24 antigen is supernatant measured at indicated day after transfection with 2 lag of pHXB2D.
Viral p24 antigen production normalized for transfection efficiency, given as a ratio of p24 antigen to CAT activity.
§ Below threshold of detection (sensitivity is 13 pg/ml). Sabatier et al. (1991) found that Tat at high concentrations was toxic to rodent neuroblastoma cells in vitro, and in vivo when injected intracerebrally in mice. That effect was dependent upon the 'basic' region of Tat, which functions in nuclear targeting and trans-activation (Green & Lowenstein, 1990) . We previously showed that exogenous Tat protein induced structural reorganization in primary cultures of embryonic rodent brain, but this effect mapped to a region of the protein (RGD sequence) different from its trans-activation domains . In contrast, in the present study we saw no toxic effects of either endogenous Tat or exogenous rTat applied at the very low concentrations that produced trans-activation. These results suggest that Tat may affect uninfected neuronal cells by several distinct mechanisms.
In glial cells the expression of extracellular matrix proteins and TGF-fil is upregulated by endogenous Tat Cupp et al., 1993) , and expression of several cellular genes is affected by Tat in non-neuronal cell types (Puri & Aggarwal, 1992; Buonaguro et al., 1992; Sastry et al., 1990; Howcroft et al., 1993; Ursini et al., 1993) . Whether the expression of endogenous genes in neuronal cells is similarly altered remains to be determined, but our results suggest neurons represent a potential target for altered cellular gene expression. Alternatively, highly restricted infection of neuronal or glial cells has been proposed to play a role in the pathogenesis of ADC (reviewed in Levy, 1993) . The finding that Tat up-regulates the highly restricted expression of HIV in transfected neuronal cells suggests that production of Tat within the nervous system may influence virus expression in non-productively infected neurons, and thus both infected and uninfected neurons may represent targets in vivo for Tat-mediated cellular dysfunction.
Recently, stimulation of the LTR by endogenous Tat has been shown in both glial cells Swingler et al., 1992; Bagasara et al., 1993) and neuronal SK-N-MC cells (Swingler et al., 1992) . In addition, the LTR has also been shown to be functional in primary rodent neurons (Corboy et al., 1992; Rattner et al., 1993) . Our results are consistent with these observations and, in addition, demonstrate efficient trans-activation by exogenous Tat protein, as well as increased virus production in Tat-expressing human neuronal cells. The responsiveness of SK-N-MC neuronal cells to nanogram quantities of recombinant protein indicates high biological activity of Tat within these cells. Circulating or intrathecal Tat has not been described in vivo, but pathological studies have shown productively infected microglia and macrophages in close contact with other CNS cell types. Tat can be released by certain infected cells (Ensoli et al., 1990 raising the possibility that local production or release may occur in vivo. In addition, cell-to-cell contact has been shown in other model systems to be effective in Tat-mediated transcellular trans-activation (Helland et al., 1991; Marcuzzi et al., 1992a, b) . Consistent with either of these mechanisms, local Tat expression has been reported at sites of close contact between HIV-infected monocytic cells and neurons in primary human brain cultures in vitro (Tardieu et al., 1992) . Thus, the ability of human neuronal cells to take up and respond to the protein suggests that local release or transcellular presentation of Tat may play a role in altering neuronal cell function in ADC.
